Basic Information
Veltassa
Regulatory Information
EMEA/H/C/004180
Authorised
July 19, 2017
May 18, 2017
9
June 11, 2024
Company Information
France
100-101 Terrasse Boieldieu Tour Franklin La Defense 8 Paris La Defense Cedex 92042 Paris
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.
Overview Summary
Veltassa is a medicine used for treating adults and adolescents aged 12 years and above with high levels of potassium in the blood (hyperkalaemia). Hyperkalaemia can cause serious heart problems and muscle weakness. Veltassa contains the active substance patiromer.